Empowering
personalized
cancer care
Our portfolio of in-house precision oncology solutions delivers rapid, reliable CGP insights in laboratories worldwide, backed by advanced proprietary bioinformatics.
Bring CGP into your lab
PGDx elio tissue complete
- 500+ solid tumor-related genes and highly accurate somatic mutation identification, including SNVs, indels, TMB, MSI, and select amplifications and translocations
- The first and only FDA cleared and CE-IVD marked comprehensive kitted solution with bioinformatics
- Research use only (RUO) outside of the U.S.
- 500+ solid tumor-related genes
- Highly accurate somatic mutation identification, including SNVs, indels, bTMB, MSI, LOH, and select amplifications and translocations
- Research Use Only (RUO)
- 33 full coding genes including SNVs, indels, MSI and select amplifications and translocations
- Results are concordant with other NGS assays across variants of clinical significance
- Research Use Only (RUO)
Maximize insights from low DNA input
Whether profiling tissue or liquid specimens, our goal is to empower clinicians and researchers with the solutions they need to elevate cancer care and advance research worldwide. We’ve channeled our precision oncology expertise into developing a suite of end-to-end offerings that deliver comprehensive and meaningful insights from low sample inputs.
Patient care ecosystem
Our products integrate optimized assay chemistry with an automated bioinformatics platform to quickly deliver reliable, actionable CGP results. PGDx elio products are available to labs worldwide to support our vision of making CGP testing readily available to all in order to elevate the standard of cancer care.
PGDx has developed a revolutionary portfolio of RUO and IVD kits powered by robust proprietary bioinformatics. By automating sample analysis and interpretation, PGDx is enabling the scalability of precision medicine with a fast, accurate, and comprehensive system.